ARICEPT ODT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ARICEPT ODT (ARICEPT ODT).
Reversible acetylcholinesterase inhibitor, increasing acetylcholine concentration in the synaptic cleft of central cholinergic neurons.
| Metabolism | Extensively metabolized by CYP3A4 and CYP2D6 isoenzymes, undergoing glucuronidation, oxidation, and N-dealkylation. |
| Excretion | Renal: 57% (as unchanged drug and metabolites); Fecal: 15%; Biliary: minor |
| Half-life | Terminal elimination half-life: 70 hours (range 50-80 hours). Clinical context: Steady-state achieved in 15-21 days; once-daily dosing maintains therapeutic concentrations. |
| Protein binding | 95-96% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Steady-state volume of distribution (Vdss): 12 L/kg (range 10-15 L/kg). Clinical meaning: Extensive tissue distribution, with preferential binding to brain tissue. |
| Bioavailability | Oral (ODT): 100% (relative to immediate-release tablets). Bioavailability is similar to conventional tablets; food does not affect absorption. |
| Onset of Action | Oral (ODT): Clinical improvement observed within 2-4 weeks, with maximum benefit in 3-6 months. |
| Duration of Action | Duration: 24 hours due to once-daily dosing. Clinical notes: Cognitive benefits persist as long as therapy continues; effects may diminish over time with disease progression. |
5 mg orally once daily; may increase to 10 mg once daily after 4-6 weeks.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (CLcr < 29 mL/min), the maximum recommended dose is 5 mg once daily. |
| Liver impairment | No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Not approved for use in pediatric patients. Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required; monitor for increased adverse effects due to age-related changes in pharmacokinetics and pharmacodynamics. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ARICEPT ODT (ARICEPT ODT).
| Breastfeeding | It is not known whether donepezil is excreted in human milk. However, in animal studies, donepezil and/or its metabolites were present in rat milk at concentrations up to 0.8 times that in maternal plasma. Caution should be exercised when administered to a nursing woman. M/P ratio: not determined in humans. |
| Teratogenic Risk | Pregnancy Category C. In animal studies, donepezil (active ingredient) showed increased incidence of stillbirths and reduced offspring survival at doses higher than the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. First trimester: potential risk unknown, but avoid unless benefit outweighs risk. Second and third trimesters: may cause uterine hypertonicity and fetal bradycardia due to cholinergic effects; use only if clearly needed. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to donepezil or piperidine derivatives.
| Precautions | Anesthesia (succinylcholine-type muscle relaxation); cardiovascular conditions (bradycardia, heart block, QT prolongation); gastrointestinal bleeding risk (NSAIDs); urinary obstruction; seizures; pulmonary conditions (COPD, asthma); syncope; hepatotoxicity; low body weight; nursing mothers; pregnancy category C. |
| Food/Dietary | No specific food restrictions. However, alcohol may increase risk of central nervous system side effects (dizziness, drowsiness). NSAIDs should be used with caution due to increased risk of gastrointestinal bleeding. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of excessive cholinergic stimulation (bradycardia, hypotension, increased secretions, gastrointestinal distress) in the mother. Fetal monitoring should include heart rate and uterine activity, especially during labor and delivery, due to potential for uterine hypertonicity and fetal bradycardia. |
| Fertility Effects | In animal studies, donepezil had no adverse effects on fertility or reproductive performance at doses up to 10 mg/kg/day (approximately 16 times the maximum recommended human dose on a mg/m2 basis). No human data available. |
| Clinical Pearls |
| Aricept ODT (donepezil) is an acetylcholinesterase inhibitor indicated for mild to moderate Alzheimer's disease. It is an orally disintegrating tablet that dissolves on the tongue without water. Dosing: 5 mg once daily initially; may increase to 10 mg/day after 4-6 weeks. Adverse effects: nausea, diarrhea, insomnia, muscle cramps, bradycardia. Monitor for syncope and GI bleeding. Concurrent NSAIDs increase GI bleed risk. Avoid in severe liver impairment. |
| Patient Advice | Take Aricept ODT once daily in the evening, just before bedtime, to minimize gastrointestinal side effects. · Place the tablet on the tongue and allow it to dissolve completely; do not swallow whole or with water. · Do not crush or chew the tablet. · If a dose is missed, skip it and take the next dose at the usual time; do not double the dose. · Common side effects include nausea, vomiting, diarrhea, and insomnia, which may improve over time. · Report any fainting spells, slow heart rate, black/tarry stools, or coffee-ground vomitus to the healthcare provider immediately. · Avoid alcohol and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen unless approved by the provider. |